Cresco Labs Price To Book vs. Current Valuation
| CRLBF Stock | USD 1.15 0.05 4.17% |
For Cresco Labs profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cresco Labs to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cresco Labs utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cresco Labs's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cresco Labs over time as well as its relative position and ranking within its peers.
Cresco |
Cresco Labs Current Valuation vs. Price To Book Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cresco Labs's current stock value. Our valuation model uses many indicators to compare Cresco Labs value to that of its competitors to determine the firm's financial worth. Cresco Labs is rated below average in price to book category among its peers. It is rated fourth in current valuation category among its peers reporting about 1,364,581,789 of Current Valuation per Price To Book. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cresco Labs' earnings, one of the primary drivers of an investment's value.Cresco Current Valuation vs. Price To Book
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Cresco Labs |
| = | 0.95 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Cresco Labs |
| = | 1.29 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Cresco Current Valuation vs Competition
Cresco Labs is rated fourth in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Drug Manufacturers—Specialty & Generic industry is currently estimated at about 9.98 Billion. Cresco Labs retains roughly 1.29 Billion in current valuation claiming about 13% of equities under Drug Manufacturers—Specialty & Generic industry.
Cresco Labs Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cresco Labs, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cresco Labs will eventually generate negative long term returns. The profitability progress is the general direction of Cresco Labs' change in net profit over the period of time. It can combine multiple indicators of Cresco Labs, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. The company was founded in 2013 and is headquartered in Chicago, Illinois. Cresco Labs operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 3300 people.
Cresco Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cresco Labs. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cresco Labs position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cresco Labs' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Cresco Labs without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Holdings Now
Portfolio HoldingsCheck your current holdings and cash postion to detemine if your portfolio needs rebalancing |
| All Next | Launch Module |
Use Investing Themes to Complement your Cresco Labs position
In addition to having Cresco Labs in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Debt ETFs Thematic Idea Now
Broad Debt ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Debt ETFs theme has 229 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Debt ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Cresco OTC Stock
To fully project Cresco Labs' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Cresco Labs at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Cresco Labs' income statement, its balance sheet, and the statement of cash flows.